Induction of cyclooxygenase-2 accounts for restraint stress-induced oxidative status in rat brain

Neuropsychopharmacology. 2003 Sep;28(9):1579-88. doi: 10.1038/sj.npp.1300187. Epub 2003 Apr 23.

Abstract

Cyclooxygenase (COX) is the rate-limiting enzyme in the metabolism of arachidonic acid into prostanoids. Although it is constitutively expressed in brain neurons, the inducible isoform (COX-2) is also upregulated in pathological conditions such as seizures, ischemia or some degenerative diseases. To assess whether COX-2 is regulated after stress, we have used adult male Wistar rats, some of which were immobilized during 6 h. An increase in PGE2 concentration occurs in brain cortex after 2-6 h of the onset of stress as well as an enhancement of COX-2 protein. Immunohistochemical studies indicate that COX-2 is expressed in the cortex and hippocampus after stress in cells with morphology of neurons. Administration of PDTC (150 mg/kg), an inhibitor of the transcription factor NF-kappaB or MK-801 (0.2 mg/kg), an N-methyl-D-aspartate receptor blocker, prevents both stress-induced increase in COX-2 activity and protein levels, suggesting an implication of these factors in the mechanism by which stress induces COX-2 in brain. To assess if COX-2 accounts for the oxidative status seen in brain after stress, a group of animals were i.p. injected with NS-398, a specific COX-2 inhibitor 1 h prior to the onset of stress. NS-398 (5 mg/kg) decreases stress-induced malondialdehyde accumulation in cortex as well as prevents the stress-induced oxidation of glutathione. Finally, NS-398 reduced Ca2+-independent inducible nitric oxide synthase (iNOS, NOS-2) activity and lowered the stress-induced accumulation of NO metabolite levels in cortex. These effects of NS-398 seem to be due to the specific inhibition of COX-2, since it has no effect on stress-induced corticosterone release, glutamate release, and NF-kappaB activation. These findings are discussed as possible damaging and/or adaptive roles for stress-induced COX-2 in the brain.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / administration & dosage
  • Blotting, Western / methods
  • Brain / enzymology*
  • Brain Chemistry*
  • Calcium / physiology
  • Cell Nucleus / drug effects
  • Cell Nucleus / metabolism
  • Cell Size / drug effects
  • Cell Size / physiology
  • Corticosterone / blood
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / pharmacology
  • Cytosol / drug effects
  • Cytosol / metabolism
  • Dinoprostone / metabolism
  • Dizocilpine Maleate / pharmacology
  • Drug Interactions
  • Electrophoretic Mobility Shift Assay / methods
  • Glutathione / metabolism
  • Immobilization / adverse effects
  • Immobilization / physiology
  • Immunohistochemistry
  • Isoenzymes / metabolism*
  • Male
  • Malondialdehyde / analysis
  • NF-kappa B / metabolism
  • Neurons / cytology
  • Neurons / drug effects
  • Neurons / enzymology
  • Neuroprotective Agents / pharmacology
  • Nitric Oxide Synthase / metabolism
  • Nitrobenzenes / pharmacology
  • Proline / administration & dosage
  • Proline / analogs & derivatives*
  • Prostaglandin-Endoperoxide Synthases / metabolism*
  • Rats
  • Rats, Wistar
  • Stress, Physiological / enzymology*
  • Sulfonamides / pharmacology
  • Thiocarbamates / administration & dosage
  • Time Factors

Substances

  • Antioxidants
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Isoenzymes
  • NF-kappa B
  • Neuroprotective Agents
  • Nitrobenzenes
  • Sulfonamides
  • Thiocarbamates
  • N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
  • prolinedithiocarbamate
  • Malondialdehyde
  • Dizocilpine Maleate
  • Proline
  • Nitric Oxide Synthase
  • Cyclooxygenase 2
  • Prostaglandin-Endoperoxide Synthases
  • Glutathione
  • Dinoprostone
  • Calcium
  • Corticosterone